AI-Powered · Launching Q3 2026

Clinical guidance for your patient, in your country

AI-powered clinical decision support that reconciles international guidelines with your local context — resistance patterns, drug availability, and regional practice standards. Not the American answer.

Free beta for the first 50 clinicians. No credit card required.

Thank you — we'll be in touch when beta opens.
225+
Clinical Conditions
70+
Guideline Sources
25
Specialties
968
Evidence Chunks

Not a search engine. A clinical reasoning engine.

Certavi uses retrieval-augmented generation (RAG) to combine a curated knowledge base of 968 clinical evidence chunks with an advanced language model. The AI doesn't guess — it retrieves specific guideline recommendations, cross-references your local resistance ecology, and returns a cited, structured answer.

Every recommendation traces back to a named guideline body and date. If the evidence isn't there, Certavi says so.

🧠

Context-aware reasoning

The AI detects infection type, patient factors, clinical setting, and your geographic location — then retrieves the right guideline for your context, not a generic answer.

🌍

Local resistance calibration

Cross-references WHO GLASS surveillance data by country and pathogen. A UTI recommendation in Dubai accounts for Gulf-region E. coli resistance patterns.

📋

Every claim cited

No hallucination. Every antibiotic recommendation, dosing suggestion, and red flag links to a named source — WHO, CDC, NICE, or one of 50+ guideline organisations.

🛡

WHO AWaRe classification

Every antibiotic flagged as Access, Watch, or Reserve. Supports antimicrobial stewardship programmes and the UN target of 70% Access antibiotic use by 2030.

Current tools give every clinician the same American answer

A UTI treatment regimen appropriate in Boston may be 60–80% resistant in Mumbai, Nairobi, or Riyadh. Leading clinical decision support tools don't account for where you practice, what drugs are available, or what your local resistance patterns look like.

Resistance patterns vary dramatically by country

E. coli fluoroquinolone resistance ranges from 15% in Northern Europe to over 70% in South Asia. One-size-fits-all guidance causes treatment failure and patient harm.

Recommended drugs may not be available

Existing tools recommend drugs that may not be on formulary, not registered, or not affordable in your market. You're left to cross-reference manually.

No API, no integration

Current tools can't be embedded into modern EHR workflows. They require context-switching at the point of care — slowing down the clinicians who need answers fastest.

Ask a question. Get a cited, localised answer.

1

Ask naturally

Type your clinical question in plain language. "Best empiric antibiotic for hospital-acquired UTI in a diabetic patient" — like asking a specialist colleague.

2

AI detects your context

Certavi identifies the infection type, patient factors, and your location. It retrieves matching guidelines and local resistance data from our 968-chunk clinical knowledge base.

3

Cited recommendation

First-line and alternative options with dosing, duration, and red flags. WHO AWaRe category flagged. Every claim cited to a named guideline and date.

225+ conditions across 25 specialties

Starting with Infectious Disease, expanding across the conditions clinicians look up most often.

Infectious Disease General Medicine Emergency Medicine Critical Care Cardiology Pulmonology Gastroenterology Nephrology Endocrinology Neurology Psychiatry Dermatology Obstetrics/GYN Pediatrics Surgery Tropical Medicine Toxicology Rheumatology Hematology Ophthalmology ENT Urology Orthopedics Pain Medicine Geriatrics Neonatology

Built on open-access clinical evidence

Every recommendation traces to a named guideline body and date. 70+ organisations including IDSA, AHA, ACC, WHO, CDC, ATS, ACOG, AAP, AAN, ACR, EULAR, ASH, AGA, KDIGO, ESC, GOLD, ADA, and many more.

WHO AWaReAntibiotic classification
WHO GLASSGlobal resistance data
WHO EMLEssential medicines
CDC GuidelinesTreatment guidance
ECDC DataEuropean resistance
NICE GuidelinesUK clinical guidance
DailyMedDrug label data
PubMed CentralPeer-reviewed evidence

Join the first 50 clinicians

We're opening beta for ID physicians and clinical pharmacists in UAE, India, and Nigeria. Free access in exchange for feedback.

Thank you — we'll be in touch when beta opens.